ClinicalTrials.Veeva

Menu

Confirmatory Study of OPC-12759 Ophthalmic Suspension

Otsuka logo

Otsuka

Status and phase

Completed
Phase 3

Conditions

Dry Eye Syndromes

Treatments

Drug: OPC-12759 Ophthalmic suspension
Drug: Hyalein Mini Ophthalmic solution

Study type

Interventional

Funder types

Industry

Identifiers

NCT00885079
037E-08-001

Details and patient eligibility

About

The purpose of this study is to verify whether OPC-12759 ophthalmic suspension is effective compared with active control in dry eye patients.

Enrollment

188 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Out patient
  2. Subjective complaint of dry eye that has been present for minimum 20 months
  3. Ocular discomfort severity is moderate to severe
  4. Corneal - conjunctival damage is moderate to severe
  5. Unanesthetized Schirmer's test score of 5mm/5minutes or less
  6. Best corrected visual acuity of 0.2 or better in both eyes

Exclusion criteria

  1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca
  2. Ocular hypertension patient or glaucoma patient with ophthalmic solution
  3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study
  4. Anticipated use of contact lens during the study
  5. Patient with punctal plug
  6. Any history of ocular surgery within 12 months
  7. Female patients who are pregnant,possibly pregnant or breast feeding
  8. Known hypersensitivity to any component of the study drug or procedural medications
  9. Receipt of any investigational product within 4 months.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

188 participants in 2 patient groups

Rebamipide
Experimental group
Description:
Instillation,4 times/day for 4 weeks
Treatment:
Drug: OPC-12759 Ophthalmic suspension
Hyaluronate
Active Comparator group
Description:
Instillation,6 times/day for 4 weeks
Treatment:
Drug: Hyalein Mini Ophthalmic solution

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems